Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Guidelines for safer handling of cytotoxics

ECCO 15 - ESMO 34

20 - 24 Sep 2009

Published: 3 Nov 2009

Views: 12209

Rating:

Save

Dr Klaus Meier - President of the European Society of Oncology Pharmacy

Dr Klaus Meier, President of the European Society of Oncology Pharmacy, discusses the society's latest work of preparing centralised guidelines for the preperation of cytotoxic treatments with managing editor Professor Gordon McVie, at ECCO 15 - ESMO 34, Berlin, 2009.

Related Videos

Metastatic bone disease: Importance of bone-targeted agents

Dr Alastair Greystoke - Newcastle University, Newcastle, UK and Prof Robert...

Metastatic bone disease: Importance of bone-targeted agents ( Dr Alastair Greystoke - Newcastle University, Newcastle, UK and Prof Robert Coleman - The University of Sheffield, Sheffield, UK )

ASCO GU 2023: CRPC updates

Dr Neal Shore, Dr Elena Castro, Prof Gerhardt Attard and Prof Eleni Efstathiou

ASCO GU 2023: CRPC updates ( Dr Neal Shore, Dr Elena Castro, Prof Gerhardt Attard and Prof Eleni Efstathiou )

Latest in PARP inhibitors and combination therapies for prostate cancer

Dr Dan George, Prof Noel Clarke, Dr Friederike Schlurmann and Prof Eleni...

Latest in PARP inhibitors and combination therapies for prostate cancer ( Dr Dan George, Prof Noel Clarke, Dr Friederike Schlurmann and Prof Eleni Efstathiou )

Latest in hormone sensitive prostate cancer

Prof Eleni Efstathiou, Prof Boris Hadaschik, Prof Gerhardt Attard and Prof...

Latest in hormone sensitive prostate cancer ( Prof Eleni Efstathiou, Prof Boris Hadaschik, Prof Gerhardt Attard and Prof Heather Payne )

3 year follow-up of the CheckMate 9ER trial: NIVO + cabozantinib vs sunitinib...

Dr Mauricio Burotto - Bradford Hill, Recoleta, Chile

3 year follow-up of the CheckMate 9ER trial: NIVO + cabozantinib vs sunitinib for first-line treatment of aRCC ( Dr Mauricio Burotto - Bradford Hill, Recoleta, Chile )

ASCO GU 2023: Latest updates in mRCC

Dr Javier Puente, Dr Bernard Escudier, Prof Stéphane Oudard, Prof Viktor...

ASCO GU 2023: Latest updates in mRCC ( Dr Javier Puente, Dr Bernard Escudier, Prof Stéphane Oudard, Prof Viktor Grünwald and Prof Toni Choueiri )

Final OS results of IMvigor130: Atezolizumab plus platinum/gemcitabine for mUC

Prof Matt Galsky - Icahn School of Medicine at Mount Sinai, New York City, USA

Final OS results of IMvigor130: Atezolizumab plus platinum/gemcitabine for mUC ( Prof Matt Galsky - Icahn School of Medicine at Mount Sinai, New York City, USA )

Gemcitabine, cisplatin plus nivolumab achieves clinical complete response in...

Prof Matt Galsky - Icahn School of Medicine at Mount Sinai, New York City, USA

Gemcitabine, cisplatin plus nivolumab achieves clinical complete response in subset of muscle-invasive bladder cancer patients ( Prof Matt Galsky - Icahn School of Medicine at Mount Sinai, New York City, USA )

Adjuvant nivolumab as standard of care for high-risk muscle-invasive urothelial...

Prof Matt Galsky - Icahn School of Medicine at Mount Sinai, New York City, USA

Adjuvant nivolumab as standard of care for high-risk muscle-invasive urothelial carcinoma after radical resection ( Prof Matt Galsky - Icahn School of Medicine at Mount Sinai, New York City, USA )

More from ecancer